Revenue: As of FY2025 Q2, the actual value is USD 119.8 M.EPS: As of FY2025 Q2, the actual value is USD -0.15.<h3>Patient Services Segment</h3><ul><li>Revenue: $55,891 for the three months ended June 30, 2025, and $108,959 for the six months ended June 30, 2025, representing a 6.5% and 3.9% increase, respectively, compared to the same periods in 2024.</li><li>Direct Costs: $51,150 for the three months ended June 30, 2025, and $98,230 for the six months ended June 30, 2025, representing a 9.9% and 2.3% increase, respectively, compared to the same periods in 2024.</li><li>Operating Income: $3,256 for the three months ended June 30, 2025, and $7,770 for the six months ended June 30, 2025.</li></ul><h3>Dispensary Segment</h3><ul><li>Revenue: $62,573 for the three months ended June 30, 2025, and $111,866 for the six months ended June 30, 2025, representing a 40.8% and 33.0% increase, respectively, compared to the same periods in 2024.</li><li>Direct Costs: $51,086 for the three months ended June 30, 2025, and $90,949 for the six months ended June 30, 2025, representing a 31.7% and 27.0% increase, respectively, compared to the same periods in 2024.</li><li>Operating Income: $11,483 for the three months ended June 30, 2025, and $20,911 for the six months ended June 30, 2025.</li></ul><h3>Clinical Trials &amp; Other Segment</h3><ul><li>Revenue: $1,338 for the three months ended June 30, 2025, and $3,383 for the six months ended June 30, 2025, representing a decrease of 20.2% and 19.7%, respectively, compared to the same periods in 2024.</li><li>Direct Costs: $65 for the three months ended June 30, 2025, and $279 for the six months ended June 30, 2025, representing a decrease of 71.6% and 55.0%, respectively, compared to the same periods in 2024.</li><li>Operating Income: $1,218 for the three months ended June 30, 2025, and $2,962 for the six months ended June 30, 2025.</li></ul><h3>Outlook</h3>The company has implemented initiatives to reduce costs and manage working capital effectively, resulting in a 3.5% reduction in SG&amp;A expenses compared to the prior year same quarter. The company expects these efforts to continue improving cash flow and operational efficiency.

Oncology Institute - CW22 | 10-Q: FY2025 Q2 Revenue: USD 119.8 M